PASSAGE BIO, INC. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
PASSAGE BIO, INC. (PASG) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $1.69 million as of 2026-03-31, per its S-4 filed 2026-07-21.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-09-03
- 2026-03-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1.69M.
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $13.29M.
- 2025-09-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $13.88M.
- 2025-06-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $14.48M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2026-03-31 | $1.69M S-4 · filed 2026-07-21 |
| 2025-12-31 | $13.29M S-4/A · filed 2026-09-03 |
| 2025-09-30 | $13.88M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $14.48M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $15.09M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $15.71M 10-K · filed 2025-03-04 |
| 2024-09-30 | $16.33M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $16.97M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $17.61M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $18.21M 10-K · filed 2024-03-04 |
| 2023-09-30 | $18.86M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $19.50M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $20.16M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $20.86M 10-K · filed 2023-03-06 |
| 2022-09-30 | $21.46M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $22.13M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $22.80M 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |